This Article  • Full text  • PDF  • Correction  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Choroidal Neovascularization  • Macular Degeneration  • Retinal/ Chorioretinal Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Ophthalmol. 2006;124:563-571.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Why are physicians interested in combining intravitreal triamcinolone with verteporfin photodynamic therapy (PDT)? Visual outcome with verteporfin PDT is poor. Nonetheless, among patients with age-related macular degeneration (AMD) and predominantly classic or pure occult choroidal new vessels (CNVs), verteporfin PDT increases one's chance of losing fewer than 15 letters on a Bailey-Lovie eye chart by approximately 40% during a 2-year follow-up, compared with sham treatment.^1-2 The Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) studies, both of which were randomized, placebo-controlled multicenter clinical trials, identified few treatment-related adverse events. In the TAP study, these included transient visual disturbances (in 22% vs 16% of controls), injection site complications (in 16% vs 6% of controls), transient photosensitivity reactions (in 3.5% vs 0% of controls), severe visual loss within 1 week of therapy (in 0.75% vs 0% of controls), and infusion-related back pain (in 2% vs . . . [Full Text of this Article]

DISEASES ASSOCIATED WITH ABNORMAL VASCULAR PERMEABILITY AND RETINAL NEOVASCULARIZATION

NON-AMD–ASSOCIATED CNVs

NONRANDOMIZED STUDIES OF AMD EYES

RANDOMIZED STUDIES OF AMD EYES

ENDOPHTHALMITIS

INCREASED INTRAOCULAR PRESSURE

CATARACT

AUTHOR INFORMATION
Marco Zarbin, MD, PhD
Author Affiliations: Institute of Ophthalmology and Visual Science, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Perspectives on Verteporfin Therapy Combined With Intravitreal Corticosteroids
Ursula Schmidt-Erfurth, Stephan Michels, and Albert Augustin
Arch Ophthalmol. 2006;124(4):561-563.
EXTRACT | FULL TEXT